Grady W M, Rajput A, Myeroff L, Liu D F, Kwon K, Willis J, Markowitz S
Department of Internal Medicine and Ireland Cancer Center, Case Western Reserve University/University Hospitals of Cleveland, Ohio 44106, USA.
Cancer Res. 1998 Jul 15;58(14):3101-4.
The transforming growth factor-beta (TGF-beta) type II receptor (RII) is a colon cancer suppressor gene that is inactivated by mutation in 90% of human colon cancers arising via the microsatellite instability (MSI) pathway of carcinogenesis. To determine the pathophysiological consequence of RII mutations, we have determined the timing of their onset among 22 MSI human colon adenomas of varying stages. No RII mutations were detected in any early MSI adenoma, including all those with simple tubular or villous histology. The earliest RII mutation detected was in a region of high-grade dysplasia but was absent from the surrounding simple adenoma. Six additional RII mutations were all found in highly progressed adenomas that contained regions of frankly invasive adenocarcinoma. These RII mutations were detected in both the advanced adenomas and their adjacent regions of carcinoma. RII mutation is a late event in MSI adenomas and correlates tightly with progression of these adenomas to cancer.
转化生长因子β(TGF-β)Ⅱ型受体(RII)是一种结肠癌抑制基因,在通过微卫星不稳定性(MSI)致癌途径发生的90%的人类结肠癌中因突变而失活。为了确定RII突变的病理生理后果,我们在22个不同阶段的MSI人类结肠腺瘤中确定了它们发生的时间。在任何早期MSI腺瘤中均未检测到RII突变,包括所有具有单纯管状或绒毛状组织学的腺瘤。检测到的最早的RII突变位于高级别发育异常区域,但周围的单纯腺瘤中没有。另外六个RII突变均在含有明显浸润性腺癌区域的高度进展性腺瘤中发现。这些RII突变在晚期腺瘤及其相邻的癌区域中均被检测到。RII突变是MSI腺瘤中的晚期事件,并且与这些腺瘤向癌症的进展密切相关。